Abstract
There are strong biologic and preclinical rationales for the development of therapeutic cancer vaccines; however, the clinical translation of this treatment strategy has been challenging. It is now understood that many previous clinical trials of cancer vaccines used target antigens or vaccine designs that inherently lacked sufficient immunogenicity to induce clinical responses. Despite the historical track record, breakthrough advances in cancer immunobiology and vaccine technologies have supported continued interest in therapeutic cancer vaccinations, with the hope that next-generation vaccine strategies will enable patients with cancer to develop long-lasting anti-tumor immunity. There has been substantial progress identifying antigens and vaccine vectors that lead to strong and broad T cell responses, tailoring vaccine designs to achieve optimal antigen presentation, and finding combination partners employing complementary mechanisms of action (e.g., checkpoint inhibitors) to overcome the diverse methods cancer cells use to evade and suppress the immune system. Results from randomized, phase 3 studies testing therapeutic cancer vaccines based on these advances are eagerly awaited. Here, we summarize the successes and failures in the clinical development of cancer vaccines, address how this historical experience and advances in science and technology have shaped efforts to improve vaccines, and offer a clinical perspective on the future role of vaccine therapies for cancer.

Key Points
Clinical translation of vaccine therapies for cancer has been challenging due to the complexity of cancer immunology and optimal vaccine design.
Advances in vaccine technology and understanding of cancer immunology support continued investigation of vaccine-based treatment strategies for cancer.

1 Introduction
Successful cancer immunotherapy ultimately requires tumor cell engagement by cytolytic effectors (T cells and antibodies) capable of specifically recognizing unique or aberrantly expressed tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs). While some patients with cancer spontaneously generate sufficient levels or function of antigen-specific T cells with the potential to generate impressive anti-tumor activity, the majority do not. One approach to ensure an adequate level and function of immune effectors is through therapeutic cancer vaccination. This form of active immunotherapy aims to generate anti-tumor immune responses directed against TAAs or TSAs [1, 2]. The idea of vaccination against cancer has a long history and was initially built on the observation that some tumors spontaneously regress in patients experiencing an acute infection [3]. More than a century ago, Dr. William Coley leveraged this observation to develop a rudimentary anti-cancer immune therapy consisting of heat-inactivated bacteria [3, 4]. How a non-specific innate immune response against bacterial products could translate into a specific anti-tumor immune response was explained subsequently by the discovery that antigen-presenting cells (APCs) (dendritic
cells (DCs)) could acquire immunogenic tumor-derived peptides released during the innate immune response. These peptides could then be used to activate anti-tumor T cells with cognate receptors [5]. This led to the hypothesis that use of tumor-derived antigens, if delivered to the immune system in a sufficiently immunogenic context (a “vaccine”), would, due to the preferential targeting of cancer cells, enable relatively safe and yet effective treatments for cancer, capable of inducing long-lasting immunity [6].

Despite this encouraging foundation, and although cancer vaccines have been the subject of intense preclinical and clinical investigation in a variety of malignancies over the past 40 years, the successful clinical translation from bench to bedside has been slow, with only two therapeutic cancer vaccines (sipuleucel-T and talimogene laherparepvec [T-VEC]) having gained regulatory approval in the United States or European Union and numerous negative phase 3 studies leading to product discontinuations. However, the interest in therapeutic cancer vaccination remains high for several reasons. First, the clinical efficacy of checkpoint inhibitors and the identification of tumor-antigen-specific T cells in treated patients now provide evidence that patients are able to prime tumor-reactive T cells and that this likely occurs spontaneously in the minority of cancer patients responding to checkpoint blockade monotherapy. Second, the identification of checkpoint-expressing T cells and checkpoint ligand-expressing tumor cells after cancer vaccine therapies suggests that combination therapies incorporating vaccines and checkpoint inhibitors may be effective, as demonstrated in preclinical studies [7–10]. Third, negative studies have provided lessons for the field moving forward, which are being applied in current trials and will be also used in future investigations. The main lessons, as recently reviewed by Hollingsworth and Jansen (2019), include the need for antigens and vaccine designs that elicit greater immunogenicity (particularly through optimal presentation of tumor antigens by professional DCs [6]) as well as combination treatment strategies to overcome multiple mechanisms of tumor-mediated immunosuppression [11]. Fourth, a deeper understanding of major histocompatibility complex (MHC)-antigen binding has evolved to allow for better vaccine design and selection of appropriate antigens. Fifth, the ability to preferentially induce type 1 anti-tumor immunity versus the more common type 2 tumor-supportive immunity has increased. Finally, although limited efficacy has been observed with the therapeutic cancer vaccine sipuleucel-T, its approval provided clinical validation of the therapeutic vaccination concept, which remains scientifically sound.

Given how recent advances may transform the track record of cancer vaccines, there is a need to summarize these developments and how they will affect the future role of vaccines. This review describes the successes and failures in the clinical development of cancer vaccines, addresses how this historical experience and advances in science and technology have shaped efforts to improve vaccines (e.g., through optimizing antigen presentation by professional APCs), and offers a clinical perspective on the future role of vaccine therapies for cancer.

2 Historical Overview of Cancer Vaccines

Several types of cancer vaccines have been developed that vary depending on the form of the delivered antigen used in the vaccine: proteins or synthetic peptides of cancer antigens, cell-based delivery of tumor antigen (e.g., modified tumor cells, DCs loaded with tumor antigens), and DNA/RNA coding for cancer antigens (e.g., plasmids, RNA, viral vectors) (Fig. 1).

2.1 Peptide- and Protein-Based Vaccines

Peptide-based vaccines are relatively easy to manufacture, but combination with potent immune adjuvants is often needed to boost immunogenicity, and the number of people who may benefit from a given peptide vaccine is restricted by human leukocyte antigen (HLA) haplotype [13]. Several phase 3 studies investigating early peptide-based vaccines have not demonstrated clinical benefit despite demonstrating some induction of immune responses against TAAs or TSAs (Table 1) [11]. Explanations for lack of clinical benefit may lie in the properties of the peptides and adjuvants used, and early peptide vaccines may have been inherently inadequate for promoting antigen presentation and generating potent and durable anti-tumor immunity [6, 60–62].

A limitation of many early peptide vaccines was the use of short peptides (< 15 amino acids), including the minimal-length epitopes required to target cytotoxic lymphocytes (CTLs) but not T helper cells [6]. Short peptide epitopes are loaded onto non-professional APCs, including T cells and B cells [6, 63]. Yet, non-professional APCs circulate to non-inflamed lymphoid organs and do not deliver costimulatory signals to optimally prime and activate CTLs, thereby promoting tolerization [63]. Furthermore, cross-presentation of short peptides by professional APCs (DCs) is not as efficient or long lasting as that for synthetic long peptides [64]. Unfortunately, vaccines based on whole proteins (including idiotype vaccines) have also been largely unsuccessful in the clinic (Table 1). This may be due to the fact that the processing and presentation of whole proteins by DCs is inferior when compared with that for shorter peptides [65].

Overall, these results have provided rationale for the development of improved peptides such as synthetic long peptides with optimized immunogenicity, alternative peptide-delivery platforms such as nanoparticles, and more potent vaccine adjuvants.
2.2 Cellular Vaccines

Commonly studied types of cell-based cancer vaccines include DCs loaded with tumor (neo)antigens, modified autologous cancer cells, and allogeneic tumor cell lines. Cell-based vaccines were among the initial types of therapeutic cancer vaccines tested. The first therapeutic cancer vaccine approved by the United States Food and Drug Administration was sipuleucel-T, a vaccine consisting of autologous peripheral blood mononuclear cells, including DCs, loaded with the prostatic acid phosphatase antigen fused with granulocyte-macrophage colony-stimulating factor (GM-CSF; an immune-cell activator). The approval of sipuleucel-T in 2010 for metastatic castration-resistant prostate cancer was based on results from the phase 3 IMPACT trial (NCT00065442) showing that treatment with sipuleucel-T significantly improved overall survival (OS) compared with placebo (median 25.8 vs. 21.7 months; hazard ratio [HR] 0.78; \( p = 0.03 \); Table 2) [66]. These results and subsequent approval provided an early clinical validation of the therapeutic cancer vaccine concept. Real-world analyses suggest that sipuleucel-T remains an effective treatment option in the current treatment landscape, which includes androgen-receptor signaling pathway inhibitors (ASPIs). A retrospective cohort analysis of men with metastatic castration-resistant prostate cancer \( (N = 6044; \) January 2013–December 2017) found that treatment with sipuleucel-T as first-line therapy or any-line therapy was associated with improved OS compared with treatment with ASPIs alone [68].

In contrast, cellular vaccines based on autologous tumor cells have not had the same success in several pivotal trials, as they either did not meet their primary endpoints or were discontinued early because of clinical futility (Table 1). One possible explanation for this lack of success is the presence of immunosuppressive factors in the irradiated tumor cells or tumor cell lysates used for these vaccines [69, 70].

2.3 Genetic Vaccines

Viruses or plasmids can act as vectors for DNA or RNA encoding TAAs [11–13]. Viruses represent a promising platform for vaccines, as virus DNA or RNA may activate DCs by triggering pattern recognition receptors [11, 71].

As monotherapy, virus vector vaccines have not yet demonstrated consistent clinical benefit as demonstrated with the experiences with PROSTVAC and PANVAC (Table 1). For example, although a virus vector vaccine (PROSTVAC-VF) demonstrated OS benefit (but not progression-free survival [PFS; primary endpoint] or response) in a randomized phase 2 study of patients with metastatic castration-resistant prostate cancer [72], this positive signal was not validated in a subsequent phase 3 study (Table 1) [11, 16]. The investigators on the phase 3 study speculated that either PROSTVAC-VF did not generate sufficient immune responses as a single agent (possibly due to the choice of antigen or disease setting) or immunity was hampered by an immunosuppressive microenvironment [16]. To address these considerations, clinical trials of PROSTVAC-VF in combination with checkpoint inhibitors [11] and/or other cancer vaccines are ongoing (NCT02933255, NCT04020094, NCT03532217, and NCT03315871). However, a recent randomized phase 2 study found that addition of a viral...
| Vaccine platform type | Autologous or allogeneic | Product/compound name | Antigen(s) | Antigen ranking | Identifier (phase, name) | Patient population | Regimens | Findings | Possible reason(s) for lack of trial success | Ref. |
|-----------------------|--------------------------|----------------------|------------|----------------|--------------------------|-------------------|----------|----------|---------------------------------|------|
| Viral vector           | Allogeneic               | PANVAC™-VF (falimarev) | MUC1, CEA 2, 13 | NCT00088660 (phase 3) | Metastatic (stage IV) pancreatic cancer; already failed prior Gem | PANVAC™-VF + GM-CSF vs. BSC or palliative chemotherapy | PROSTVAC ± GM-CSF vs. placebo | Primary endpoint (OS) not met | Tumor burden (inappropriate population for vaccine monotherapy) | [15] |
| Viral vector           | Allogeneic               | PROSTVAC-V/F         | PSA 22     | NCT01322490 (phase 3, PROSPECT) | Asymptomatically/minimally symptomatic mCRPC | Primary endpoint (OS): Placebo: 34.3 months PROSTVAC: 34.4 months (HR comparison with placebo: 1.01 [95% CI 0.84–1.20, \( p = 0.47 \)) | PROSTVAC + GM-CSF: 33.2 months (HR comparison with placebo: 1.02 [95% CI 0.86–1.22, \( p = 0.59 \)]) | Insufficient immune response or negative regulatory influences in the TME | Insufficient immune response or negative regulatory influences in the TME | [16] |
| Viral vector           | Allogeneic               | CMB305               | NY-ESO-1 10 | NCT02609984 (phase 2, IMDZ-C232) | NY-ESO-1 + soft tissue sarcoma | CMB305 + aezolizumab vs. aezolizumab | Primary endpoints (OS, PFS), CMB305 + aezolizumab vs. aezolizumab: OS: 18.2 months vs. 18.0 months PFS: 2.8 months vs. 1.6 months | Imbalances in patient/disease characteristics: combination arm had more advanced disease and more prior lines of chemotherapy | Potential for prolonged OS in the control arm relative to expected due to increasing availability of multiple life-extending treatments since the study was designed | [17] |
| Cell-based (tumor cell) | Allogeneic               | Belagenpumatucel-L (Lucanix™) | –          | –               | NCT00676507 (phase 3) | Stage III/IV NSCLC; stable disease following frontline, platinum-based chemotherapy | Belagenpumatucel-L vs. placebo | Primary endpoint (OS), belagenpumatucel-L vs. placebo: median 20.3 months vs. 17.8 months (HR 0.94; 95% CI 0.73–1.20; \( p = 0.59 \)); at second interim analysis, study was terminated for futility | Study design (late enrollment after induction therapy; single-agent therapy) | Study did not require prior radiation within 6 months of randomization, which may have improved OS | [18] |
| Vaccine platform type | Autologous or allogeneic | Product/compound name | Antigen(s) | Antigen ranking<sup>a</sup> | Identifier (phase, name) | Patient population | Regimens | Findings | Possible reason(s) for lack of trial success | Ref. |
|-----------------------|--------------------------|-----------------------|------------|-----------------------------|-------------------------|-------------------|----------|---------|---------------------------------------------|-----|
| Cell-based (tumor cell) | Allogeneic | GVAX® | – | – | NCT0089856 (phase 3, VITAL-1) | Metastatic, hormone-refractory prostate cancer | GVAX® vs. docetaxel + prednisone | Median survival (GVAX® vs. docetaxel + prednisone): 20.7 months vs. 21.7 months ($p = 0.78$) Study terminated based on futility analysis showing $< 30\%$ chance of meeting primary endpoint Terminated early from lack of therapeutic effect | – | [11, 19] |
| Cell-based (tumor cell) | Allogeneic | GVAX® | – | – | NCT00133224 (phase 3; VITAL-2) | Taxane-naïve, metastatic, hormone-refractory prostate cancer patients with pain | GVAX® + docetaxel vs. docetaxel and prednisone | OS (GVAX® + docetaxel vs. docetaxel and prednisone): 12.2 months vs. 14.1 months ($p = 0.01$) Accrual and treatment with GVAX® stopped because of IDMC recommendation Terminated early from lack of therapeutic effect | – | [11, 19] |
| Cell-based (tumor cell) | Allogeneic | Canvaxin™ (CancerVax) | – | – | NCT00052130 (phase 3, MMAIT-III) | Completely resected stage III melanoma | Canvaxin™ + BCG vs. BCG | Based on DSMB recommendation, study was terminated (low probability demonstrating significant improvement in Canvaxin™-containing treatment arm) Population heterogeneity (burden of disease, heterogeneity of disease, immunological response) | – | [20, 21] |
| Vaccine platform type | Autologous or allogeneic | Product/compound name | Antigen(s) | Antigen ranking\(^a\) | Identifier (phase, name) | Patient population | Regimens | Findings | Possible reason(s) for lack of trial success | Ref. |
|-----------------------|--------------------------|------------------------|------------|------------------------|-------------------------|-------------------|----------|---------|---------------------------------------------|------|
| Cell-based (tumor cell) | Allogeneic | Canvax™ (CancerVax) | – | – | NCT00052156 (phase 3, MMAIT-IV) | Completely resected stage IV melanoma | Canvax™ + BCG vs. BCG | Primary endpoint (OS), Canvax™ + BCG vs. BCG: median 38.6 months vs. 34.9 months (HR 1.04; 95% CI 0.80–1.35; \(p = 0.77\)) | High survival in both treatment arms may be a result of selection bias, beneficial effect of metastasectomy, and/or use of BCG in control treatment arm | [20, 22] |
| Cell-based (tumor lysate) | Allogeneic | Melacine (theraccine) | – | – | – (phase 3) | Resected, intermediate-thickness, node-negative melanoma | After surgery: Melacine + DETOX adjuvant therapy vs. no further treatment | Primary endpoint (DFS, OS), vaccine vs. no treatment DFS: 107/300 events (tumor recurrences or deaths) vs. 114/300 (HR 0.92; Cox-adjusted \(P_2 = 0.51\)) OS: Not mature at time of publication | Study design (inadequately powered to detect small, clinically meaningful differences; methodology for staging regional nodes) Population heterogeneity | [23] |
| Cell-based (tumor lysate) | Allogeneic | Melacine (theraccine) | – | – | – (phase 3) | Stage IV melanoma with \(\geq 1\) measurable lesion(s), ECOG PS 0–1 | Melacine vs. DTIC, cisplatin, BCNU, and tamoxifen | Median survival (melacine vs. chemotherapy): 9.4 months vs. 12.3 months \((p = 0.16)\) | – | [24] |
| Cell-based (tumor cell) | Allogeneic | Algenpantucel-L (HyperA-cute® platform) | – | – | NCT01072981 (phase 3, IMPRESS) | Surgically resected pancreatic cancer, stage I or II (per AJCC) | Algenpantucel-L + SOC (Gem + 5FU chemoradiation) vs. SOC alone | Primary endpoint (OS), algenpantucel-L + SOC vs. SOC: 30.4 months vs. 27.3 months; primary endpoint was not achieved | – | [25] |
| Vaccine platform type | Autologous or allogeneic | Product/compound name | Antigen(s) | Antigen ranking<sup>a</sup> | Identifier (phase, name) | Patient population | Regimens | Findings | Possible reason(s) for lack of trial success |
|-----------------------|--------------------------|-----------------------|------------|-----------------------------|-------------------------|-------------------|---------|---------|----------------------------------------|
| Cell-based (virus-augmented tumor cell) | Allogeneic | VMCL | – | – | – | Cutaneous melanoma; stage IIB or stage III (per AJCC); regional nodal involvement without evidence of systemic metastatic disease | VMCL vs. observation | Median RFS: In eligible patients: 6.9 vs. 3.6 years (HR 0.86; 95% CI 0.70–1.07; p = 0.17) In ITT patients: 6.98 vs. 4.37 years (HR 0.89; 95% CI 0.72–1.09; p = 0.27) Median OS: In eligible patients: 12.6 vs. 7.3 years (HR 0.81; 95% CI 0.64–1.02; p = 0.07) In ITT patients: >8.45 vs. 7.34 years (HR 0.83; 95% CI 0.67–1.04; p = 0.11) | Better survival of control treatment arm in phase 3 study compared with phase 2 study |
| Cell-based (virus-augmented tumor cell) | Allogeneic | VMO | – | – | – (phase 3) | Stage II melanoma (per IUAC) with positive lymph nodes | VMO vs. control (vaccinia virus alone) | Median disease-free interval, VMO vs. control: 38.0 months vs. 37.0 months (p = 0.99) | Population heterogeneity (potential differences for male vs. female patients) |
| Cell-based (virus-augmented tumor cell) | Allogeneic | VMO | – | – | – (phase 3) | Stage III melanoma (per AJCC) | VMO vs. control (vaccinia virus alone) | Median disease-free interval, VMO vs. control: 20.7 months vs. 26.9 months (p = 0.61) Median OS, VMO vs. control: 50.2 months vs. 41.3 months (p = 0.79) Median OS, 10-year follow-up, VMO vs. control: 7.71 years vs. 7.95 years (p = 0.70) | Population heterogeneity (retrospective subset analysis showed that a subgroup of men may have a survival advantage with VMO) |
| Vaccine platform type | Autologous or allogeneic | Product/compound name | Antigen(s) | Antigen ranking<sup>a</sup> | Identifier (phase, name) | Patient population | Regimens | Findings | Possible reason(s) for lack of trial success | Ref. |
|-----------------------|-------------------------|-----------------------|------------|-----------------------------|-------------------------|-------------------|----------|---------|---------------------------------------------|-----|
| Cell-based (RNA electronegated DC) | Autologous | Rocapuldencel-T (AGS-003) | – | – | NCT01582672 (phase 3, ADAPT) | Newly diagnosed metastatic RCC | Rocapuldencel-T + standard therapy vs. standard therapy alone | Primary endpoint (OS), rocapuldencel-T + standard therapy vs. standard therapy alone: median 27.7 months vs. 32.4 months (unadjusted HR 1.10; 95% CI 0.83–1.46; adjusted HR 1.06; 95% CI 0.79–1.40) | Insufficient long-term follow-up/potential delayed treatment effect | [30] |
| Cell-based (DC) | Autologous | Peptide-loaded DC vaccine | Several MHC class I- and class II-restricted peptides (9 or 10 mer)<sup>b</sup> | Includes 44, 8, 20, 16, 14 | – | Metastatic (stage IV) melanoma | DC vaccine vs. DTIC | Primary endpoint (OR): < 6% in both treatment arms | Following first interim analysis, study was prematurely closed (recommendation of external Data Monitoring and Safety Board because of extremely low probability of reaching study goals) | Population heterogeneity (significant differences in subgroups defined by performance status and HLA haplotype) | [31] |
| Vaccine platform type | Autologous or allogeneic | Product/compound name | Antigen(s) | Antigen ranking$^a$ | Identifier (phase, name) | Patient population | Regimens | Findings | Possible reason(s) for lack of trial success | Ref. |
|-----------------------|--------------------------|-----------------------|------------|---------------------|--------------------------|-------------------|----------|---------|----------------------------------------|------|
| DNA vaccine           | Allogeneic               | Allovectin-7®         | HLA-B7 and β2 microglobulin | –                   | NCT00395070 (phase 3)   | Recurrent stage III or stage IV melanoma | Allovectin-7® vs. chemotherapy alone (DTIC or TMZ) | No significant improvement in objective response rate at ≥ 24 weeks (primary endpoint) or OS (secondary endpoint); based on this outcome, Allovectin program has been terminated | – | [32–34] |
| Ganglioside           | Allogeneic               | GM2-KLH (GMK)         | GM2        | –                   | EORTC 18961 (phase 3)   | Stage II melanoma | GM2-KLH/ QS-21 vs. observation after resection of primary tumor >1.5 mm | Primary endpoint (RFS), GM2-KLH/ QS-21 ($n = 627$) vs. observation ($n = 627$): Second interim analysis: 135 events vs. 132 events (HR 1.00; 98% CI 0.75–1.34; $p = 0.99$); trial was stopped for futility Final analysis: 205 vs. 204 events (HR 1.03; 98% CI 0.84–1.25; $p = 0.81$) | Vaccination schedule (i.e., impact of multiple vaccinations may be deleterious) | [35] |
| Vaccine platform type | Autologous or allogeneic | Product/compound name | Antigen(s) | Antigen rankinga | Identifier (phase, name) | Patient population | Regimens | Findings | Possible reason(s) for lack of trial success | Ref. |
|-----------------------|--------------------------|-----------------------|------------|------------------|--------------------------|-------------------|----------|----------|------------------------------------------|------|
| Ganglioside allogeneic | GM2-KLH (GMK)             | GM2                   | –          | –                | Intergroup trial E1694/S9512/CS09801 (phase 3) | Resected stage IIb/III melanoma (per AJCC) | GM2-KLH/ QS-21 vs. HDI therapy | Primary endpoint (RFS), GM2-KLH/ QS-21 vs. HDI therapy: In eligible patients: 151/389 (39%) events vs. 98/385 (25%) events (HR 1.47; 95% CI 1.14–1.90; log-rank one-sided p < 0.05 in favor of HDI [p = 0.0015]) In ITT population: HR 1.49 (p < 0.05 in favor of HDI [p = 0.00045]) P values for RFS crossed protocol-specified lower boundary, resulting in study termination Primary endpoint (OS), GM2-KLH/ QS-21 vs. HDI therapy: In eligible patients: (HR 1.52; 95% CI 1.07–2.15; log-rank one-sided p = 0.01 in favor of HDI) In ITT population: HR 1.38 (p = 0.02) | – | [36] |
| Protein allogeneic Abagovomab | CA-125 (cleaved and released domain of MUC16) | – | NCT00418574 (phase 3, MIMOSA) | Stage III–IV epithelial ovarian, primary peritoneal, or fallopian tube cancer in first complete clinical remission | Abagovomab vs. placebo | Primary endpoint (RFS), abagovomab (n = 593) vs. placebo (n = 295); 374 recurrence events vs. 180 recurrence events (HR 1.10; 95% CI 0.92–1.32; p = 0.30) | Study design (combination therapies and multi-antigen approaches remain reasonable approaches to study) | – | [37] |
| Vaccine platform type | Autologous or allogeneic | Product/compound name | Antigen(s) | Antigen ranking\(^a\) | Identifier (phase, name) | Patient population | Regimens | Findings | Possible reason(s) for lack of trial success |
|-----------------------|--------------------------|-----------------------|------------|------------------------|-------------------------|-------------------|----------|---------|---------------------------------------------|
| Protein (anti-idiotypic antibody) | Allogeneic | BEC2 | GD3 | 40 | NCT00037713 (phase 3, SILVA) | Limited-disease SCLC | BEC2/BCG vs. observation | Primary endpoint (OS), BEC2/BCG vs. observation: median 14.3 vs. 16.4 months (HR 1.12; 95% CI 0.91–1.37; \(p = 0.28\)) | Study design (imbalance in patient characteristics; choice of adjuvant or anti-idiotypic approach; single-antigen approach) Population heterogeneity and study design (GD3 is present in only ~60% of SCLC tissues and patients were not stratified by GD3 expression) Insufficient immune response (1/3 of patients developed humoral response) |
| Protein (idiotype) | Autologous | MyVax (GTOP-99) | Patient-specific idiotypic conjugated to KLH (recombinant DNA technique) | 7 | NCT00017290 (phase 3) | Previously untreated, advanced-stage (Ann Arbor stage III or IV) FL | MyVax + GM-CSF vs. control (KLH + GM-CSF) | Primary endpoint (PFS), MyVax vs. control: HR 0.98, 95% CI 0.72–1.33; \(p = 0.89\) | Insufficient humoral immune response (immune response observed in 41% of patients) Population heterogeneity (patients with better immune response had better PFS) Study design (choice of adjuvant) |
| Protein (idiotype) | Autologous | Mitumprotimut-T (Specifid) | Patient-specific idiotypic conjugated to KLH (recombinant DNA technique) | 7 | – (phase 3) | Treatment-naïve or relapsed/refractory CD20+ FL, WHO grade I–3; candidate for rituximab | Mitumprotimut-T + GM-CSF vs. placebo (GM-CSF) | Primary endpoint (TTP), mitumprotimut-T vs. placebo: 9.0 months vs. 12.6 months (HR 1.38; 95% CI 1.05–1.82; \(p = 0.02\)) | Imbalance in FLIPI risk groups Product (antigen and/or adjuvant selection) Insufficient immune response/inhibitory immune microenvironment |
| Vaccine platform type | Autologous or allogeneic | Product/compound name | Antigen(s) | Antigen ranking$^a$ | Identifier (phase, name) | Patient population | Regimens | Findings | Possible reason(s) for lack of trial success | Ref. |
|-----------------------|--------------------------|-----------------------|------------|---------------------|-------------------------|--------------------|----------|---------|---------------------------------------------|------|
| **Protein (idiotype)** | Autologous               | BiovaxID®             | Patient-specific idiotype conjugated to KLH (hybridoma technique) | 7 | NCT00091676 (phase 3) | Advanced stage FL in first remission (CR or CR unconfirmed) after chemotherapy | BiovaxID® + GM-CSF vs. control (KLH + GM-CSF) | Primary endpoint (DFS), BiovaxID® + GM-CSF vs. control: For all 177 randomly assigned patients (includes 60 patients who did not receive vaccination): 23.0 months vs. 20.6 months (HR 0.81; 95% CI 0.56–1.16; $p = 0.26$) For the 117 patients who received vaccination: 44.2 months vs. 30.6 months (HR 0.62, 95% CI 0.39–0.99; $p < 0.05$ [$p = 0.047$]) | Study design (control treatment arm [KLH + GM-CSF vs. placebo]) Product (tumor Ig isotype may influence immunogenicity of vaccine) | [41] |
| **Protein**           | Allogeneic               | THERATOPE® STn        | 56 | NCT00003638 (phase 3) | MBC; previously received chemotherapy and had CR, PR, or no disease progression | STn-KLH vs. KLH | Primary endpoints (TTP and OS), STn-KLH vs. KLH: TTP: 3.4 months vs. 3.0 months (Cox $p = 0.35$) OS: 23.1 months vs. 22.3 months (Cox $p = 0.92$) | Study design (KLH as control arm rather than no treatment) Tumor burden (advanced metastatic disease) Treatment duration (continued vaccination beyond primary progression may have been advantageous) | [42] |
| Vaccine platform type | Autologous or allogeneic | Product/com-pound name | Antigen(s) | Antigen ranking $^a$ | Identifier (phase, name) | Patient population | Regimens | Findings | Possible reason(s) for lack of trial success | Ref. |
|-----------------------|--------------------------|------------------------|------------|----------------------|--------------------------|-------------------|----------|---------|------------------------------------------|------|
| Protein               | Allogeneic               | GSK2132231A           | Recombinant | 8                    | NCT00796445 (phase 3, DERMA) | Resected, MAGE-A3-positive, stage III melanoma | GSK2132231A + AS15 vs. placebo | Primary end-point (DFS), GSK2132231A + AS15 vs. placebo: In overall population: median 11.0 months vs. 11.2 months (HR 1.01; 95% CI 0.88–1.17; $p = 0.86$) In patients with potentially predictive gene signature: median 9.9 months vs. 11.6 months (HR 1.11; 95% CI 0.83–1.49; $p = 0.48$) | Product (choice of antigen, immunostimulant) Insufficient/absent immune response Target population (too advanced for antigen-specific immunotherapeutic alone) | [43] |
| Protein               | Allogeneic               | GSK1572932A           | Recombinant | 8                    | NCT00480025 (phase 3, MAGRIT) | Resected, MAGE-A3-positive, NSCLC | GSK1572932A + AS15 vs. placebo | Primary end-point (DFS), GSK1572932A + AS15 vs. placebo: In overall population: median 60.5 months vs. 57.9 months (HR 1.02; 95% CI 0.89–1.18; $p = 0.74$) In patients who did not receive chemotherapy: median 58.0 months vs. 56.9 months (HR 0.97; 95% CI 0.80–1.18; $p = 0.76$) In patients with potentially predictive gene signature: not evaluated, as predictive gene signature could not be identified | Initial positive treatment effect in phase 2 trial may be a result of limited sample size and/or unnoticed imbalances across treatment groups | [44] |
Table 1 (continued)

| Vaccine platform type | Autologous or allogeneic | Product/compound name | Antigen(s) | Antigen ranking | Identifier (phase, name) | Patient population | Regimens | Findings | Possible reason(s) for lack of trial success | Ref. |
|-----------------------|--------------------------|-----------------------|------------|----------------|--------------------------|-------------------|----------|---------|-------------------------------------------|------|
| Protein               | Allogeneic               | G17DT (Insegia)       | Gastrin-17 | –              | NCT00044031 (phase 3)   | Untreated with locally advanced, recurrent, or metastatic pancreatic cancer | G17DT + Gem vs. placebo + Gem | Primary endpoint (OS), G17DT + Gem vs. placebo + Gem: 178 days vs. 201 days (HR 1.10; p = 0.10) | Population heterogeneity (anti-G17 antibody levels correlated with OS) | [21] |
| Synthetic peptide     | Allogeneic               | Tecemotide (L-BLP25, StimuVax) | MUC1 | 2              | NCT00409188 (phase 3, START) | Unresectable stage III NSCLC | Tecemotide vs. placebo | Primary endpoint (OS), tecemotide vs. placebo: 25.8 months vs. 22.4 months (adjusted HR 0.89; 95% CI 0.77–1.03; p = 0.11) | Population heterogeneity (possibly more favorable effect in patients receiving concurrent as opposed to sequential chemoradiotherapy) Clinical hold potentially resulted in underestimated treatment effect | [45, 46] |
| Synthetic peptide     | Allogeneic               | Tecemotide (StimuVax; L-BLP25) | MUC1 | 2              | NCT00925548 (phase 3, STRIDE) | ER-positive and/or PgR-positive, inoperable, locally advanced, recurrent, or metastatic BC in post-menopausal women | Tecemotide + hormonal therapy vs. hormonal therapy | Sponsor permanently terminated trial following clinical hold | Safety concerns | |
| Synthetic peptide     | Allogeneic               | GV1001 | hiTERT | 23 | ISRCTN4382138 (phase 3, TeloVac) | Locally advanced or metastatic pancreatic cancer; ECOG PS 0–2 | Chemotherapy alone (Gem and capecitabine); chemotherapy with sequential GV1001 + GM-CSF; chemotherapy with concurrent GV1001 + GM-CSF | Primary endpoint (OS): Chemotherapy alone vs. sequential GV1001 + GM-CSF: median 7.9 months vs. 6.9 months (HR 1.19, 98.25% CI 0.97–1.48; p = 0.05) Concurrent GV1001 + GM-CSF: median 8.4 months (HR 1.05; 98.25% CI 0.85–1.29; p = 0.64; overall log-rank of $\chi^2_{df} = 4.3; p = 0.11$) | Nature of disease (early metastasizing, rapidly progressive may limit time to develop immune response; dense stromal reaction may impede/restrict synergistic potential of chemotherapy and GV1001) | [21, 47–49] |
| Vaccine platform type | Autologous or allogeneic | Product/compound name | Antigen(s) | Antigen ranking | Identifier (phase, name) | Patient population | Regimens | Findings | Possible reason(s) for lack of trial success | Ref. |
|-----------------------|--------------------------|------------------------|-----------|----------------|-------------------------|-------------------|----------|---------|--------------------------------------------|------|
| Synthetic peptide (16 mer) | Allogeneic | GV1001 | hTERT | 23 | NCT00358566 (phase 3, Primovax) | Advanced, unresectable pancreatic cancer; ECOG PS 0–1 | Gem alone vs. Gem with sequential GV1001 + GM-CSF | Preliminary data showed no survival benefit in GV1001 group vs. chemotherapy alone | – | [47, 49] |
| Synthetic peptide (14 mer) | Allogeneic | Rindopepimut (CDX-110) | EGFRvIII | 5 | NCT01480479 (phase 3, ACT IV) | Newly diagnosed, EGFRvIII-expressing glioblastoma | TMZ + rindopepimut + GM-CSF vs. control (TMZ alone) | Primary endpoint (OS), TMZ + rindopepimut + GM-CSF vs. control: Study was terminated at the second interim analysis for futility; In the ITT population: median 17.4 months vs. 17.4 months (HR 0.89, 95% CI 0.75–1.07; p = 0.22); In the MRD population: median 20.1 months vs. 20.0 months (HR 1.01; 95% CI 0.79–1.30; p = 0.93) | Patients in control treatment arm fared better in this study than matched control datasets; Study design (control arm [KLH vs. inactive placebo]; TMZ use [treatment-induced lymphopenia may reduce immunotherapy efficacy]; vaccine started after radiotherapy vs. as early as possible); Product (single antigen rather than multi-peptide vaccine or other combination approaches) | [50, 51] |
| Synthetic peptide | Allogeneic | Elpamotide | VEGFR2 | 70 | UMIN000002500 (phase 2/3, PEGASUS-PC) | Locally advanced or metastatic pancreatic cancer | Elpamotide + Montanide™ ISA 51 VG vs. placebo (saline + Montanide™ ISA 51 VG) | Primary endpoint (OS), elpamotide + Montanide™ ISA 51 VG vs. placebo: median 8.36 months vs. 8.54 months (HR 0.87; 95% CI 0.49–1.56; H-F p = 0.92) | Population heterogeneity (subgroup analyses suggested that patients with strong injection site reactions may benefit from the vaccine, but these patients were limited in number); Study design (use of Montanide™ ISA 51 VG in control arm; single vs. multiple tumor targets) | [52] |
| Vaccine platform type | Autologous or allogeneic | Product/compound name | Antigen(s) | Antigen rankinga | Identifier (phase, name) | Patient population | Regimens | Findings | Possible reason(s) for lack of trial success | Ref. |
|-----------------------|--------------------------|-----------------------|------------|------------------|--------------------------|-------------------|----------|---------|---------------------------------------------|------|
| Synthetic peptides    | Allogeneic               | Peptide vaccine       | Tyrosinase, gp100, MART-1/ melan-A | 20, 16, 14 | ECOG E4697 study | Locally advanced (stage III) and/or stage IV melanoma with no evidence of disease after complete surgical resection | Peptide vaccine + Montanide™ ISA 51 ± GM-CSF vs. placebo ± GM-CSF | Secondary objective (RFS), peptide vaccine vs. placebo in HLA-A2+ patients: median 11.5 months vs. 9.8 months (HR 0.96; 95% repeated CI 0.74–1.23; \( p = 0.71 \)) | Population heterogeneity (sites of metastases, baseline immune status) Insufficient immune response or lack of relevance of immune response Product (adjuvant selection, administration) | [53] |
| Synthetic peptide     | Allogeneic               | Nelipepimut-S (E75; NeuVax™) | HER2 | 6 | NCT01479244 (phase 3, PRESENT) | T1–T3, node-positive BC with low to intermediate HER2 expression | Nelipepimut-S + GM-CSF vs. GM-CSF | Primary endpoint (DFS), nelipepimut-S (\( n = 376 \)) vs. placebo (\( n = 382 \)): 37 recurrence events vs. 24 recurrence events; no significant difference in DFS events (HR 1.564; 95% CI 0.96–2.55; \( p = 0.07 \)) | Study design (protocol-specified annual imaging instead of clinical assessment per ASCO guidelines hastened interim analysis [clinical significance of image-only recurrence events unclear]) | [54, 55] |
| Protein-peptide complex | Autologous               | Vitespen (HSPPC-96, Oncophage) | gp96-peptide complex | NCT00033904 (phase 3) | ---- | RCC at high risk of recurrence after nephrectomy | Vitespen vs. observation | Primary endpoint (RFS), vaccine vs. observation: 37.7% (136/361) vs. 39.8% (146/367) (HR 0.92; 95% CI 0.73–1.17; \( p = 0.51 \)) | Study design (higher than expected number of patients with metastatic disease) Population heterogeneity (more targeted recruitment may have allowed enrollment of patients with earlier stage disease and better prognosis) | [56] |
Table 1 (continued)

| Vaccine platform type | Autologous or allogeneic | Product/compound name | Antigen(s) | Antigen ranking | Identifier (phase, name) | Patient population | Regimens | Findings | Possible reason(s) for lack of trial success | Ref. |
|-----------------------|--------------------------|-----------------------|------------|----------------|-------------------------|-------------------|----------|----------|--------------------------------------|------|
| Protein-peptide complex | Autologous | Vitespen (HSPPC-96, Oncophage) | gp96-peptide complex | – | NCT00039000 (phase 3) | Stage IV melanoma, with expected resectability of some/all lesions to obtain ≥ 7 g of cancer | Vitespen vs. physician’s choice (DTIC/TMZ and/or IL-2 and surgery) | Primary endpoint (OS), vaccine vs. physician’s choice: HR 1.16; 95% CI 0.69–1.71; p = 0.32 | Study execution (49% success rate for vaccine production based on suggested minimum threshold of four administrations in animal models) Population heterogeneity (exploratory analyses showed that patients with earlier stages of disease may have benefited from the vaccine) | [57] |
| Protein-peptide complex | Autologous | Vitespen (HSPPC-96, Oncophage) | gp96-peptide complex | – | NCT01814813 (phase 2) | Surgically resectable, recurrent glioblastoma | Vitespen + bevacizumab vs. bevacizumab alone | Primary endpoint (OS), vaccine + bevacizumab vs. bevacizumab alone at interim analysis: 7.5 months vs. 10.7 months (HR 2.06; 95% CI 1.18–3.60; p = 0.008); study terminated for futility | – | [58] |
| Oncolytic virus | Allogeneic | pexastimogene devacirepvec (Pexa-Vec) | – | – | NCT02562755 (phase 3) | Advanced HCC without prior systemic therapy | Pexa-Vec vs. sorafenib | Interim futility analysis determined that the primary objective (OS) was not likely to be met | Difficult-to-treat population Imunosuppressive environment (liver) Imbalance between arms in salvage therapies received | [59] |
vaccine to checkpoint inhibition did not yield a survival benefit in soft tissue sarcoma [17]. There is very limited clinical investigation of the PANVAC vaccine for pancreatic tumors (NCT00669734).

Like viral platforms, plasmid vector-based vaccines have intrinsic adjuvant immunogenicity because the nucleic acid itself may be immunostimulatory, triggering an innate immune response [73]. Other advantages of this platform are enhanced stability, ease of manufacturing, induction of intracellular antigen expression, and if full-length genes are utilized, there is no HLA restriction. Despite these advantages, there has been limited late-stage investigation of DNA or RNA vaccines to date. The DNA vaccine Allovectin-7®°, which contains DNA sequences for HLA-B7 and β2 microglobulin, did not improve objective response rate or OS compared with chemotherapy in patients with advanced melanoma in a phase 3 trial, leading to termination of the development program. There have since been numerous improvements in DNA and RNA delivery technologies (e.g., electroporation) and more modern nucleic acid vaccines have been tested in early-stage studies, as described in Sect. 3.

### 2.4 Other Types of Cancer Vaccines

In contrast to the therapeutic cancer vaccines described previously, some vaccines used in the treatment of cancer do not deliver defined tumor antigens to generate anti-tumor immunity, but nevertheless, generate an immune response. For example, intravesical immunotherapy (i.e., vaccination) with Mycobacterium bovis bacillus Calmette–Guérin (BCG) is approved for the treatment of certain types of bladder cancer. The mechanism of action of BCG immunotherapy has not been well understood, but recent data indicate that BCG improves the activation and exhaustion status of tumor-specific T cells [74].

Another cancer vaccine approach involves strategies to modify or inflame tumor cells by intratumoral administration of oncolytic viruses. In 2015, the oncolytic viral vaccine T-VEC, a herpes virus genetically modified to express GM-CSF [13], was licensed for the treatment of patients with unresectable melanoma. The approval of T-VEC was based on the phase 3 OPTiM trial (NCT00769704) demonstrating that a higher proportion of patients treated with T-VEC versus GM-CSF had a durable clinical response (≥ 6 months continuously and beginning within the first year; 16.3% vs. 2.1%, respectively; \( p < 0.001 \) Table 2). There was also a trend for improved OS in the T-VEC group (23.3 vs. 18.9 months; \( p = 0.051 \)) [67]. The mechanism of action for oncolytic viral vaccines such as T-VEC is different to that of other notable cancer vaccines. This form of “in situ” vaccination results in the killing of tumor cells by the virus and the release of tumor antigens [75, 76].
effects lead to the immune-mediated regression of distant tumor lesions, presumably either through amplification of previously activated host-immunity and/or the priming of new anti-tumor immune responses [75–77]. Evidence for tumor-specific T cell induction after T-VEC treatment was observed in a clinical study of patients with stage IIIc and stage IV melanoma. In this study, a patient with a complete response after T-VEC injection had an increase in MART-1-specific effector T cells, both in the injected target lesion and in a nontarget lesion [77].

3 The Evolution of Cancer Vaccine Development: Current Strategies Based on Historical Experience and Scientific Advances

The limited success of therapeutic cancer vaccines despite decades of development by academia and industry raises the questions of why expectations have not been fulfilled and how barriers to successful development can be overcome. Advances in our understanding of antigen immunogenicity, the importance of antigen presentation, and the dynamics of how cancer cells evade and suppress the host immune system suggest that previous studies may have used suboptimal antigen targets, vaccine designs, and/or trial designs (including patient populations). In 2015, Melief et al. formulated a list of attributes that cancer vaccines would need to have to be successful [6]. In brief, these attributes stress the importance of broad stimulation of CTLs and T helper cells through two mechanisms: (1) selection of appropriate antigens that induce both T cell populations and (2) rational vaccine designs that achieve concentrated delivery of tumor antigens to activated DCs, where epitopes derived from exogenous tumor antigens can be loaded onto both MHC class I (through the cross-presentation pathway) and MHC class II molecules to stimulate CTLs and T helper cells, respectively (Fig. 2) [6, 78]. Over the last decade, therapeutic cancer vaccine strategies have improved, incorporating better immunogenicity, antigen selection, and structural design to meet these criteria.

3.1 Selecting the Appropriate Antigen

Choosing optimal antigens has been described as the most important consideration in the design of therapeutic vaccines [11]. Antigen selection affects critical vaccine properties, including the ability to generate a strong and broad immune response, target cancer stem cells to prevent relapse, and avoid off-target effects on normal cells. Optimal antigen discovery is hindered by the limited number of suitable immunogenic antigens fitting these criteria within the context of an immense number of potential antigens [14]. Current strategies aim to efficiently identify appropriate antigens for cancer vaccines either in the form of “ideal” shared tumor antigens or more personalized neoantigens.

Shared TAAs are self-proteins with preferential or abnormal expression in cancer cells versus normal cells [11], and these have been the primary type of antigen tested in clinical trials [11]. An important advance in the field occurred in 2009 when a National Cancer Institute (NCI) Pilot Project developed a list of nine “ideal” cancer antigen criteria, which

| Vaccine platform type | Product name | Antigen(s) Identifier (phase, name) | Patient population | Regimens | Findings | Reference |
|-----------------------|--------------|------------------------------------|--------------------|----------|----------|-----------|
| Cell-based            | Sipuleucel-T | PA2024 NCT00065442 (phase 3, IMPACT) | Metastatic castration-resistant prostate cancer | Sipuleucel-T vs. placebo | Primary endpoint (overall survival): Median of 25.8 months (sipuleucel-T) vs. 21.7 months (placebo); HR 0.78; 95% CI 0.61–0.98; \( p = 0.03 \) | [66] |
| Cell-based (oncolytic virus) | Talimogene laherparepvec (T-VEC) | N/A NCT00769704 (phase 3, OPTiM) | Unresected stage IIIB to IV melanoma | Intralosomal T-VEC vs. subcutaneous recombinant GM-CSF | Primary endpoint (durable response rate): 16.3% (T-VEC) vs. 2.1% (GM-CSF); odds ratio 8.9; \( p < 0.001 \) | [67] |

CI confidence interval, GM-CSF granulocyte-macrophage colony-stimulating factor, HR hazard ratio, N/A not applicable
based vaccine is being planned (Table 3) [95]. Additionally, survival benefit [84, 94], and a phase 3 study of a WT1-phase 2 studies of WT1 vaccines have shown trends toward specific immune responses [79–93]. Notably, randomized (HER2)/neu, are ongoing and have demonstrated tumor-1 (MUC1) and human epidermal growth factor receptor 2 factor, was considered the most encouraging antigen among the 75 assessed [14]. Early-stage trials of cancer vaccines ranked 23 out of 75 possible antigens by the NCI list [14]. This vaccine failed to generate sufficient immune responses and did not improve OS compared with chemotherapy alone in patients with pancreatic cancer [49].

Development of the NCI's prioritized list provides the impetus to investigate highly ranked TAAs. Within this list, Wilms’ tumor 1 (WT1) protein, a zinc finger transcription factor, was considered the most encouraging antigen among the 75 assessed [14]. Early-stage trials of cancer vaccines targeting WT1 or other highly ranked TAAs, such as mucin 1 (MUC1) and human epidermal growth factor receptor 2 (HER2)/neu, are ongoing and have demonstrated tumor-specific immune responses [79–93]. Notably, randomized phase 2 studies of WT1 vaccines have shown trends toward survival benefit [84, 94], and a phase 3 study of a WT1-based vaccine (human telomerase reverse transcriptase [hTERT]) ranked 23 out of 75 possible antigens by the NCI list [14].

Several peptide-based vaccines with negative phase 3 results targeted tumor antigens that would have been retrospectively deemed not a high priority target by consensus NCI criteria [14]. For example, the GV1001 peptide vaccine targeted a TAA (human telomerase reverse transcriptase [hTERT]) and did not improve OS compared with chemotherapy alone in patients with pancreatic cancer [49].

A limitation of shared TAAs is that they are autologous antigens, and immune self-tolerance mechanisms may deplete or eliminate TAA-specific T cells with high functional avidity, resulting in a tolerated T cell repertoire with relatively low reactivity toward the TAA [6]. Although increased immunogenicity has enabled TAA-based vaccines to break this tolerance, parallel advances in genomics have now allowed the efficient identification of another class of cancer antigen, termed neoantigen, which is not subject to immune self-tolerance mechanisms [6]. Neoantigens are aberrant peptides that arise from genetic and epigenetic alterations (point mutations, insertions/deletions, gene fusions/translocations, splice variants, and post-translational modifications) in cancer cells [97]. Because these alterations are not part of the normal exome or transcriptome, the encoded neoantigens are tumor specific. Mutated peptides that are dissimilar to the self-proteome are more likely to be seen as novel by the immune system, and therefore be more immunogenic, compared with those that are similar to the self-proteome [98].

Broadly, candidate neoantigens are identified through a two-step process. First, whole exome and transcriptome sequencing of normal and cancerous cells allows identification of tumor-specific mutations (i.e., the mutanome) [100]. Next, neoepitopes are prioritized by in silico prediction of the binding affinity of each mutant peptide to MHC molecules. Advances in massive parallel sequencing have dramatically accelerated this process, enabling feasible and high-throughput identification of tumor neoantigens for cancer vaccines [99, 100]. Because of these technological advancements and parallel innovations in cancer immunotherapy, the Human Vaccines Project (a public–private partnership with a goal of accelerating the development of cancer vaccines) ranked neoantigens as a high priority target for clinical translation [100].

Several early-stage clinical studies in patients with solid tumors showed that personalized neoantigen vaccines are safe, feasible, and able to augment neoantigen-specific T cell responses [101–108]. Notably, although most neoantigen vaccine clinical studies have been restricted to cancer types with high mutation burdens (e.g., melanoma) and thus more neoantigen potential, recent data from patients with glioblastoma also show neoantigen immune responses for cold tumors with low mutation burdens [106, 109]. Whether the generation of immune responses to neoantigens is therapeutically relevant remains uncertain, as mutations in expressed genes rarely result in the presentation of T cell targetable neoantigens on the cell surface [110] and few neoantigen vaccine studies have attempted to verify that the mutated peptide is present on the surface of the tumor cell. One of the few studies to assess the presence of mutated peptides on the tumor cell surface found 643 genomic mutations among 15 patients with glioblastoma but did not identify any of these mutations in the HLA peptidome by mass spectrometry [111]. Although this study found that neoepitopes induced T cell responses [111], the failure to identify surface mutated peptides calls into question the role of neoantigens for tumors with low tumor mutation burden. Overall, these initial studies of neoantigen cancer vaccines have provided proof of concept, have provided rationale for larger studies.
Therapeutic Cancer Vaccines: A Review

and continued research and development [11], and have highlighted a need for neoantigen vaccine studies to verify the presence of targetable, mutated peptides on the tumor cell surface.

There are several ongoing efforts to optimize neoantigen vaccines. Cost-effective and efficient workflows and algorithms for more accurate prediction of which mutated peptides will stimulate the most potent anti-tumor T cell

---

Fig. 2 Optimal antigen processing and presentation by DCs is important for effective immune-mediated tumor cell destruction [6]. Antigens enter DCs through multiple mechanisms, including endocytosis, phagocytosis, pinocytosis, and receptor-mediated uptake. These antigens are processed by DCs into peptide fragments (epitopes) before being loaded onto MHC class I molecules through cross priming or MHC class II molecules through the classical exogenous presentation pathway. T cell recognition of these epitopes occurs via binding between the TCR and the peptide-MHC complex on the DC. Following epitope recognition, CD40L expressed by CD4+ T cells activates DC-expressed CD40 to promote DC maturation and IL-12 secretion. This subsequently stimulates CD28 signaling and activation of CD8+ T cells. When the TCR of an effector CD8+ T cell binds to a tumor cell, an immunological synapse forms and lytic granules are secreted by the effector CD8+ T cell, resulting in tumor cell destruction. Note: Cytosolic and vacuolar pathways for cross-presentation have been described. The figure presents the cytosolic pathway as it has been suggested this is the predominant pathway for cross-presentation [78]. [Figure adapted with permission of the Journal of Clinical Investigation, from “Therapeutic Cancer Vaccines,” Cornelis J.M. Melief et al, Volume 125, Issue 9, 2015; permission conveyed through Copyright Clearance Center, Inc.]

CD, cluster of differentiation, CLIP, class II-associated invariant chain peptide, DC, dendritic cell, ER, endoplasmic reticulum, FasL, Fas ligand, IL, interleukin, MHC, major histocompatibility complex, SLP, synthetic long peptide, TAP, transporter of antigen processing, TCR, T cell receptor, TNF, tumor necrosis factor, TRAIL, TNF-related apoptosis-inducing ligand
| Vaccine platform type | Product name | Antigen(s) | Identifier (phase, name) | Patient population | Enrollment | Regimens | Primary outcome measures |
|-----------------------|--------------|------------|--------------------------|--------------------|------------|----------|-------------------------|
| Cell-based (trivalent DC) | – | Autologous tumor stem cells, survivin, and hTERT | NCT03548571 (phase 2/3, DEN-STEM) | Glioblastoma IDH wild-type, with unmethylated MGMT-gene promoter | 60 | Trivalent DC immunization vs. radiotherapy with concomitant and adjuvant temozolomide | PFS |
| Peptide | GP96 heat shock protein-peptide complex | – | NCT04206254 (phase 2/3) | Liver cancer | 80 | GP96 vaccination after surgery vs. no treatment after surgery | 2-year recurrence-free survival rate |
| Adenoviral vector containing the herpes simplex virus thymidine kinase gene | ProstAtak® (AdV-tk) + valacyclovir | – | NCT01436968 (phase 3) | Localized prostate cancer (intermediate risk or one NCCN high-risk feature) due to undergo standard prostate-only EBRT | 711 | ProstAtak® (AdV-tk) + valacyclovir + radiation therapy ± androgen deprivation therapy vs. placebo + valacyclovir + radiation therapy ± androgen deprivation therapy | DFS |
| Cell-based (bacterial) | BCG Tokyo-172 strain solution | – | NCT03091660 (phase 3) | Stage 0/0is/1 urothelial carcinoma | 969 | Tokyo-172 strain BCG (arm 2) vs. Tokyo-172 strain BCG solution with priming (arm 3) vs. TICE® BCG (arm 1) | Time to high-grade recurrence for arm 1 vs. arm 2, and arm 2 vs. arm 3 |
| Cell-based (DCs) | DCs plus autologous tumor RNA | – | NCT01983748 (phase 3) | Stage T2, T3, or T4 melanoma of the uvea | 200 | Autologous DCs loaded with autologous tumor RNA vs. SOC | Prolongation of OS |
| Cell-based (tumor cell) | OncoVAX® | – | NCT02448173 (phase 3) | Stage II colon cancer | 550 | OncoVAX® and surgery vs. surgery | DFS |
| Oral vaccine (tablet) derived from pooled blood | Hepcortespenlisimut-L (Hepko-V5) | – | NCT02232490 (phase 3, Hepko-V5) | Advanced hepatocellular carcinoma | 120 | Hepcortespenlisimut-L vs. placebo | Changes in plasma AFP |
| Cell-based (bacterial) | BCG | – | NCT04165317 (phase 3) | High-risk non-muscle-invasive transitional cell carcinoma of the urothelium and complete resection of all Ta/T1 papillary disease | 999 | PF-06801591 + BCG induction and maintenance (arm A) vs. PF-06801591 + BCG induction only (arm B) vs. BCG induction and maintenance (arm C) | DFS (arm A vs. arm C and arm B vs. arm C) |
| Vaccine platform type | Product name | Antigen(s) | Identifier (phase, name) | Patient population | Enrollment | Regimens | Primary outcome measures |
|-----------------------|--------------|------------|--------------------------|--------------------|------------|----------|-------------------------|
| Cell-based (bacterial) | OncoTICE®/ImmuCYST®/TheraCys® | – | NCT02948543 (phase 3, ANZUP 1301) | Confirmed high-grade pTa or stage pT1 (any grade) non-muscle-invasive bladder cancer and transurethral resection | 500 | Intravesical BCG (arm A) vs. intravesical BCG + mitomycin C | DFS |
| Cell-based (bacterial) | BCG-Medac® | – | NCT03799835 (phase 3, ALBAN) | High-risk non-muscle-invasive urothelial carcinoma | 614 | BCG vs. BCG + atezolizumab | RFS |
| Cell-based (DCs) | nDC | – | NCT02993315 (phase 3, MIND-DC) | Stage III cutaneous melanoma, classified as IIIB or IIC disease | 210 | nDC vaccination vs. placebo | RFS |
| Cell-based (tumor cell) | Vigil | – | NCT03495921 (phase 3, VITA) | Patients aged ≥ 2 years with histologically confirmed ESFT and relapsed/refractory to 1 line of systemic chemotherapy | 114 | Vigil + irinotecan and temozolomide vs. irinotecan and temozolomide | PFS |
| Cell-based (bacterial) | BCG | – | NCT03528694 (phase 3, POTOMAC) | High-risk transitional cell carcinoma of the urothelium of the urinary bladder confined to the mucosa/submucosa; for patients who have received complete resection of all Ta/T1 papillary disease prior to randomization | 973 | Durvalumab plus BCG (induction + maintenance) vs. durvalumab plus BCG (induction only) vs. BCG | DFS for durvalumab plus BCG (induction + maintenance) vs. BCG |
| Cell-based (bacterial) | TICE® BCG OncoTICE® | – | NCT03711032 (phase 3, KEYNOTE-676) | Histologically confirmed non-muscle-invasive (T1, high grade Ta and/or CIS) transitional cell carcinoma of the bladder previously treated with BCG induction therapy followed by persistent/recurrent disease and has received cystoscopy/TURBT to remove all resectable disease | 1525 | BCG (induction and maintenance) plus pembrolizumab vs. BCG monotherapy (induction and maintenance) | CRR by blinded independent central review, EFS |
| Vaccine platform type | Product name | Antigen(s) | Identifier (phase, name) | Patient population | Enrollment | Regimens | Primary outcome measures |
|-----------------------|--------------|------------|--------------------------|--------------------|------------|----------|-------------------------|
| TAA vaccine           | OSE2101/ Tedopi/ EP-2101 EP2101 IDM-2101 | HLA A2 restricted "optimized epitopes" from ACE, HER2, MAGE2, MAGE3, and P53 | NCT02654587 (phase 3, ATALANTE-1) | Locally advanced NSCLC (stage III) unsuitable for radiotherapy, or metastatic (stage IV) with disease recurrence/progression after an immune checkpoint inhibitor and platinum-based chemotherapy | 363 | OSE2101 vs. docetaxel or pemetrexed | OS |
| Analog peptide vaccine | Galinpepimut-S (SLS-001) | WT1 | NCT04229979 (phase 3) | AML in second complete remission or in second complete remission with incomplete platelet recovery | 116 | Galinpepimut-S vs. best available therapy (observation, HMA monotherapy, venetoclax monotherapy, or low-dose cytarabine) | OS |
| Cell-based (bacterial) | BCG | – | NCT03664869 (phase 3, Finnblander-10) | High-risk non-muscle-invasive bladder cancer confined to the bladder (high-grade Ta/any T1 following 2nd resection) | 300 | BCG instillation and maintenance therapy vs. sequential BCG and EMDA mitomycin C | Bladder cancer recurrence rate |

Includes studies that are planned or are recruiting patients.

ACE angiotensin-converting enzyme, AFP α-fetoprotein, AML acute myelogenous leukemia, BCG bacillus Calmette-Guérin, CIS carcinoma in situ, CRR complete response rate, DC dendritic cell, DFS disease-free survival, EBRT external beam radiation therapy, EFS event-free survival, EMDA electromotive drug administration, ESFT Ewing sarcoma family of tumors, HER2 human epidermal growth factor receptor 2, HLA human leukocyte antigen, HMA hypomethylating agent, hTERT human telomerase reverse transcriptase, IDH isocitrate dehydrogenase, MAGE melanoma-associated antigen, MGMT O6-methylguanine-DNA methyltransferase, NCCN National Comprehensive Cancer Network, nDC natural dendritic cell, NSCLC non-small-cell lung cancer, OS overall survival, PFS progression-free survival, RFS recurrence-free survival, SOC standard of care, TAA tumor-associated antigen, TURBT transurethral resection of the bladder tumor, WT1 Wilms' tumor 1.
response are being investigated [112, 113]. Innovative neoantigen vaccine designs are also being explored, with preclinical data showing that DNA-based neoantigen vaccines can generate robust CTL-driven anti-tumor responses and delay tumor progression [114]. Furthermore, results from a combined approach using both TAAs and neoantigens in patients with newly diagnosed glioblastoma suggest that mixtures of antigenic targets may provide sustained anti-tumor responses by central memory CTLs and T helper cells [111].

### 3.2 Evolution of Therapeutic Cancer Vaccine Designs

Over the past decade, vaccine designs have evolved to elicit effective immune responses characterized by potent and broad stimulation of CTLs and T helper cells as well as enhanced antigen presentation by activated DCs. These optimizations, summarized below for the most encouraging platforms, are currently being used in the next generation of therapeutic cancer vaccines with the hope they will lead to improved immune and clinical responses compared with historical experience.

#### 3.2.1 Peptide Vaccines

In response to the observation that short peptides and long protein sequences resulted in inadequate clinical activity (Table 1), extension of the amino acid sequence beyond the minimal-length CTL epitope or other short sequences has been shown to achieve more concentrated and selective delivery of antigens to DCs with sustained presentation [63]. Vaccination with synthetic long peptides has induced more robust and durable T cell responses compared with the minimal-length epitopes in preclinical models [6, 115, 116]. Because of these advantages, modern synthetic peptide vaccine designs commonly use at least one long peptide [6, 117], representing an important advance over the use of minimal-length peptide constructs.

Amino acid substitutions on the native TAA sequence (epitope enhancement) can be rationally implemented to improve binding stability to APCs and thus increase the likelihood of successful antigen presentation to T cells [60, 61, 87]. Modification of the peptide structure to increase amphiphilicity may also increase peptide immunogenicity, as demonstrated in the development of the BiVax peptide/polynosinic-polycytidylic acid (poly I:C) subunit vaccine [118].

Recent evidence demonstrates that T helper cells play critical roles in induction of strong and long-lasting immune-mediated anti-tumor responses [119, 120]. In particular, targeting T helper type 1 cells is thought to be optimal, as they have been shown to have potent effects in inducing and maintaining anti-tumor immunity, whereas T helper type 2 cells may actually promote neoplastic transformation in certain contexts [121]. While early peptide vaccine designs only targeted CTLs, modern synthetic peptide vaccines now typically include CTL and helper peptides in an effort to increase immunogenicity and improve clinical efficacy [85, 87].

#### 3.2.2 DC Vaccines

The evolution of DC cancer vaccines was sparked by increased insight into DC biology and technology advances, recently reviewed in 2017 by Garg et al., who classified the development of this DC vaccine platform according to first-generation, second-generation, and next-generation designs [122]. Notably, sipuleucel-T, the only approved DC-based vaccine (licensed in 2010), was considered by Garg et al. to be on the borderline of first- and second-generation designs.

In brief, first-generation designs were characterized by the use of immature monocyte-derived DCs: the development of maturation cocktails enabled the consistent use of mature monocyte-derived DCs in second-generation constructs [122]. This advancement was important because compared with immature DCs, mature DCs express higher levels of MHC and costimulatory molecules, produce more cytokines, and traffic more efficiently to lymph nodes [123]. All these effects make mature DCs more potent activators of the immune system, which in turn has been found to translate to improved efficacy in clinical trials. Indeed, Garg et al. reported that in many trials, second-generation DC vaccines produced higher response rates and increased median OS compared with first-generation designs [122].

The transition from second-generation to next-generation DC vaccines was characterized by the use of patient-derived specific DC subsets (e.g., myeloid and plasmacytoid DCs) with specialized functionalities (antigen presentation, interferon responses, migratory capacity) superior to those of monocyte-derived DCs [122, 124]. This transition was enabled by incorporation of antibody-coated magnetic bead technology for more rapid and pure isolation of native DCs compared with older techniques such as density centrifugation [122, 124]. Next-generation DC vaccines are currently being tested in clinical trials [124]; results presented so far from phase 1 or 2 studies have demonstrated their feasibility and safety, with some encouraging OS durations observed [124–127]. A phase 3 study (NCT02993315) comparing next-generation DC vaccination with placebo as adjuvant therapy for patients with stage III melanoma will provide more robust survival data and clarify the clinical efficacy of this vaccination approach [124].

More recently, a strategy employing intratumoral DCs as part of an in situ vaccine has been described. This in situ vaccine approach uses a triplet consisting of injection of FMS-like tyrosine kinase 3 ligand at the target lesion to
generate accumulation of intratumoral DCs, local tumor irradiation to load the intratumoral DCs with TAAs released from dying tumor cells, and injections of a Toll-like receptor (TLR) agonist at the target lesion to drive intratumoral DC activation [128]. In essence, this triplet creates a DC-based vaccine at the site of the tumor [128]. This in situ vaccine was recently evaluated in a phase 1 clinical trial (NCT01976585) for patients with advanced stage indolent non-Hodgkin lymphoma, where it was reported to be well tolerated and capable of producing durable regressions at distant tumor sites via an abscopal effect [128]. Of 11 patients who received the in situ vaccine, eight had partial or complete remissions of the treated tumor with regard to the non-treated tumors, six patients had stable disease or minor regressions lasting 3–18 months, and three achieved remission [128].

### 3.2.3 Genetic Vaccines

The main limitations of early nucleic acid–based vaccine designs have been limited uptake of the nucleic acid by DCs and other cells, either because of low transfection efficiency or degradation [11], and the resultant low immunogenicity observed in clinical trials. For DNA- or RNA-based vaccines, several upgrades have allowed the prospect of improved transfection rates and immunogenicity as described by Hollingsworth and Jansen [11] including use of electroporation, sonoporation, nanoparticles [129], gene guns, microneedle arrays, needle-free injection [130], and liposomal encapsulation.

Based on encouraging phase 2b data showing significantly higher regression rates of cervical intraepithelial neoplasia compared with placebo [11, 131], a DNA-based vaccine using electroporation is currently being evaluated in two phase 3 studies (REVEAL 1, NCT03185013; REVEAL 2, NCT03721978) to treat patients with precancerous lesions of the cervix (high-grade squamous intraepithelial lesions associated with human papillomavirus). Early-stage studies are evaluating DNA-based vaccines using electroporation for a variety of solid tumors (NCT03199040, NCT03122106, NCT03532217, NCT0349085, NCT02204098, and NCT04397003). In phase 1 studies, RNA-based vaccines using either electroporation [108] or RNA-lipoplexes [132] to improve systemic DC targeting have demonstrated encouraging immune-mediated anti-tumor activity for patients with melanoma.

Other methods to improve the immunogenicity of nucleic acid–based vaccines have been recently reviewed by Lopes et al. [133]. To break immune tolerance and target multiple TAAs, DNA vaccines encoding xenoantigens or chimeric proteins have been studied [133]. In animal models, chimeric DNA vaccines have induced potential anti-tumor effects [134, 135], and one such vaccine is approved for the treatment of canine melanoma. Numerous human clinical trials are currently evaluating polyepitope DNA vaccines, which aim to induce a broad T cell response through the simultaneous delivery of multiple antigens [133].

### 3.3 The Role of Adjuvants

Effective therapeutic cancer vaccines rely on antigen presentation and activation of the immune system by DCs; however, suppression of DC maturation and function is a hallmark of cancer immune evasion [136]. Even worse, many subsets of DCs are in an immature state and produce “self”-tolerizing messages to the immune system. Therefore, cancer vaccines without DC activators may actually convey a tolerizing signal to the immune system and diminish endogenous immune response [137]. Thus, activation of DCs with immunostimulatory adjuvants is a critical component of many cancer vaccine strategies [136].

An advance in the design of cancer vaccines has been the inclusion of adjuvants that can trigger pattern recognition receptors, such as TLRs, nod-like receptors (NLRs), retinoic acid-inducible gene (RIG)-I-like receptors (RLRs), stimulator of interferon genes (STING), and CD40 agonists, to signal the immune system that the vaccine antigen is both foreign and dangerous [2, 6, 11, 138]. This is especially important for peptide vaccine platforms, because unlike microbe- or nucleic acid–based platforms, peptide antigens do not inherently present danger signals to the immune system [11]. Without this signal, the immune system cannot mount a strong anti-tumor response due to a lack of costimulation and efficient antigen presentation by DCs.

Novel adjuvants, such as TLR agonists, have been tested in preclinical and clinical studies [11], with evidence of potent DC activation and generation of strong T cell responses [139, 140]. An important finding is that co-delivery of the peptide antigen and TLR agonist, either through peptide-agonist conjugation or nanocarriers, results in improved DC targeting, DC activation, and trafficking to draining lymph nodes [141, 142]. Recent peptide vaccine formulations have primarily employed Montanide ISA-51, TLR agonists such as poly I:C or CpG, or immunostimulatory cytokines such as GM-CSF as adjuvants [117]; however, there is currently no consensus about what the optimal adjuvant is for a given peptide vaccine [117], representing a potentially fruitful avenue of research to further optimize vaccine design.
4 Future Perspective

The historical experience with therapeutic cancer vaccines coupled with fundamental advances in understanding of the immunobiology of cancer have provided a roadmap for future vaccine development. The key challenges that must be overcome are identifying antigens and vaccine vectors that will lead to strong and broad T cell responses, tailoring vaccine designs to achieve optimal antigen presentation by professional APCs, and finding combination partners employing complementary mechanisms of action to overcome the diverse methods that cancer cells use to evade and suppress the immune system [11]. In recent years, the field has risen to meet this challenge, with many encouraging upgrades to antigen selection and vaccine designs. Combination strategies with a variety of other agents, including immunotherapies, chemotherapies, and radiotherapy, have also been investigated in preclinical and clinical studies [11]. These refinements will need to be validated in appropriately designed, randomized, phase 3 studies. Consequently, despite decades of lackluster progress, therapeutic cancer vaccines are now primed to emerge as central components of cancer therapy due to these advancements in biology and technology.

Therapeutic cancer vaccines may fill a niche not currently met by conventional therapies or other immunotherapies. Clinical experience suggests that vaccines are safe and can elicit long-term immune memory responses important for durable disease control [11]. This experience coupled with the existence of multiple mechanisms of immunosuppression in advanced disease suggest that vaccines may be particularly well-suited early in the course of the disease or in the minimal residual disease setting. Indeed, when there has been apparent benefit from cancer vaccines, it has been in the minimal residual disease setting [143].

Another potential role for vaccination is to augment lost immunity to oncogenic proteins where immunity is lost through oncogenesis [144, 145]. Cancer vaccines could also potentially be used to prevent disease through the targeting of antigens whose upregulation is associated with resistance to therapy [146].

Therapeutic cancer vaccines may also help actualize the full potential of immunotherapies that have already had an impact in the clinic [12]. For example, it is known that although checkpoint inhibitors are effective for “hot” tumors characterized by infiltration of primed and active T cells, they lack potency for “cold” tumors that do not have these immune cells. By priming tumor-specific T cells and mobilizing them to the tumor, essentially turning “cold” tumors “hot,” vaccine therapies restore the ability of checkpoint inhibitors to unleash T cell-mediated tumor destruction [12, 128]. Similarly, whereas chimeric antigen receptor (CAR)-T cell therapy is now an established therapy for certain hematologic malignancies, demonstrating efficacy in solid tumors has been difficult. A recent preclinical study showed that injection of a vaccine consisting of amphiphile CAR-T ligands primed CAR-T cells and enhanced their efficacy in solid tumor models [147].

There are several encouraging avenues to further improve the efficacy of therapeutic cancer vaccines. One currently being investigated is the use of heterologous prime boosting whereby a TAA is first delivered by a specific vector during a priming vaccination and then subsequently delivered by a different vector during later boosting vaccinations [11]. This strategy overcomes immune-mediated inactivation of the initial viral vector, allowing repeated vaccination against the TAA target and potentially enhanced immunogenicity [11]. Another approach to improve the efficacy of cancer vaccines is the development of strategies to induce antibody responses with anti-tumor activity. For example, one study found that multi-site injections enhanced the number of TAA-specific antibodies compared with single bolus injections [148].

Finally, it is anticipated that cancer vaccines will benefit from advances in the speed, cost, and efficiency of molecular sequencing, artificial intelligence, and cellular engineering. These techniques may enable the quick and complete interrogation of the immune response (changes in immune milieu, tumor immune escape mechanisms) to a cancer vaccine, allowing subsequent vaccines to be tailored based on this response [149].

Acknowledgements Medical writing assistance was provided by Andrew Gomes, PhD, of Ashfield Healthcare Communications, a UDG Healthcare plc company, and funded by Sumitomo Dainippon Pharma Oncology, Inc.

Declarations

Funding Medical writing assistance was funded by Sumitomo Dainippon Pharma Oncology, Inc.

Conflict of interest MAM is a consultant/advisory board member for Roche/Genentech, AstraZeneca/MedImmune, Celldix, Eli Lilly, and Gritstone and has received research funding from Merck, BMS, Eutibics, and Alphavax. WRG and DAM declare that they have no conflict of interest.

Ethics approval Not applicable.

Consent to participate Not applicable.

Availability of data and material Not applicable.

Code availability Not applicable.

Author contributions All authors were involved in the development of the content and direction of this article. Additionally, all authors
revised it critically for important intellectual content; approved the final version; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

References

1. Butterfield LH. Cancer vaccines. BMJ. 2015;350:h988.
2. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008;8(5):351–60.
3. Hopton Cann SA, van Netten JP, van Netten C. Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J. 2003;79(938):672–80.
4. McCarthy EP. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006;26:154–8.
5. Ott PA, Wu CJ. Cancer vaccines: steering T cells down the right path to eradicate tumors. Cancer Discov. 2019;9(4):476–81.
6. Melief CJM, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer vaccines. J Clin Investig. 2015;125(9):3401–12.
7. Ali OA, Lewin SA, Dranoff G, Mooney DJ. Vaccines combined with immune checkpoint antibodies promote cytotoxic T-cell activity and tumor eradication. Cancer Immunol Res. 2016;4(2):183–100.
8. Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, Chai Y, et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J Immunother. 2015;38(1):1–11.
9. Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine JD, et al. PD-1/PD-L1 blockade with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J Immunother. 2011;34(5):409–18.
10. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17):5323–37.
11. Chawla SP, Tine BAV, Pollack S, Ganjoo KN, Elias AD, Riedel RF, et al. A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1+ soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival. J Clin Oncol. 2019;37(15_suppl):11011.
12. Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhasz E, Ramlau R, et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer. 2015;51(16):2321–9.
13. Ogi C, Aruga A. Clinical evaluation of therapeutic cancer vaccines. Hum Vacc Immunother. 2013;9(5):1049–57.
14. Faries MB, Mozzillo N, Kashani-Sabet M, Thompson JF, Kelley MC, DeConti RC, et al. Long-term survival after complete surgical resection and adjuvant immunotherapy for distant melanoma metastases. Ann Surg Oncol. 2017;24(13):3991–4000.
15. Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL. Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol. 2012;39(3):296–304.
16. Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, et al. Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. J Clin Oncol. 2019;37(13):1051–61.
17. Morton DL, Mozzillo N, Thompson JF, Kelley MC, Faries M, Wagner J, et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MVC) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol. 2007;25(18_suppl):8508.
18. Chawla SP, Tine BAV, Pollack S, Ganjoo KN, Elias AD, Riedel RF, et al. A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1+ soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival. J Clin Oncol. 2019;37(15_suppl):11011.
19. Vishnu P, Tan WW. Update on options for treatment of metastatic castration-resistant prostate cancer. Oncotarget Ther. 2010;3:39–51.
20. Wallack MK, Sivanandham M, Bilusic M, Heery C, Schlom J, Gulley JL, et al. Phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1+ soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival. J Clin Oncol. 2019;37(15_suppl):11011.
30. Figlin R, Nicolette C, Tannir N, Yokodi S, Chen D, Master V, et al. Interim analysis of the phase 3 ADAPT trial evaluating capraludencel-T (AGS-003), an individualized immunotherapy for the treatment of newly-diagnosed patients with metastatic renal cell carcinoma (mRCC). Ann Oncol. 2017;28(suppl_5):11370.

31. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Brocker EB, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol. 2006;17(4):563–70.

32. Leach B. OncLive. Allovectin falters in late-stage melanoma trial. Published August 13, 2013. https://www.onclive.com/view/allovectin-falters-in-late-stage-melanoma-trial. Accessed 24 June 2020.

33. Bedikian AY, Del Vecchio M. Allovectin-7 therapy in metastatic melanoma. Expert Opin Biol Ther. 2008;8(6):839–44.

34. Powell K. DNA vaccines—back in the saddle again? Nat Biotechnol. 2004;22(7):799–801.

35. Eggermont AM, Suciu S, Rutkowski P, Marsden J, Santinami M, Corrie P, et al. Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. J Clin Oncol. 2013;31(30):3831–7.

36. Kirkwood JM, Ibrahim JG, Somasjan A, Sondak VK, Agarwala SS, Ernstoff MS, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19(9):2370–80.

37. Sabbatini P, Harter P, Scambia G, Seshouli J, Meier W, Wirtz W, et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of theAGO OVAR, COGI, GINECO, and GEICO— the MIMOSA study. J Clin Oncol. 2013;31(12):1554–61.

38. Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Gue´rme´rin in responding patients with limited-dis ease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971–08971B; Silva Study). J Clin Oncol. 2005;23(28):6854–64.

39. Levy R, Ganjoo KN, Leonard JP, Vose JM, Flinn IW, Ambinder RF, et al. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. J Clin Oncol. 2014;32(17):1797–803.

40. Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol. 2009;27(18):3036–43.

41. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. 2011;29(20):2787–94.

42. Miles D, Roche H, Martin M, Perren TJ, Cameron DA, Glasp J, et al. Phase III multicenter clinical trial of the siatly-TN (Stn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist. 2011;16(8):1092–100.

43. Dreno B, Thompson JF, Smithers BM, Santinami M, Jouary T, Gutzmer R, et al. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(7):916–29.

44. Vansteenkiste JF, Cho BC, Venakasa T, De Pas T, Zielinski M, Kim MS, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(6):822–35.

45. Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(1):59–68.

46. Mitchell P, Thatcher N, Socinski MA, Wasilewska-Tesluk E, Horwood K, Szczesna A, et al. Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol. 2015;26(6):1134–42.

47. Tagliamonte M, Petrizio A, Tornesello ML, Buonaguro FM, Buonaguro LN. Antigen-specific vaccines for cancer treatment. Hum Vacc Immunother. 2014;10(11):3332–46.

48. Xia W, Wang X, Xu Y, Jiang F, Xu L. L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review. J Thorac Dis. 2014;6(10):1513–20.

49. Middleton G, Silcock P, Cox T, Valle J, Wadley J, Propper D, et al. Gemcitabine and capicitabine with or without telomerasepeptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (Telovac): an open-label, randomised, phase 3 trial. Lancet Oncol. 2014;15(8):829–40.

50. Weller M, Butowsky N, Tran DD, Recht LD, Lim M, Hirte H, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017;18(10):1373–85.

51. Choi BD, Archer GE, Mitchell DA, Heimberger AB, McLendon RE, Bignner DD, et al. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol. 2009;19(4):713–23.

52. Yamaue H, Tsunoda T, Tani M, Miyazawa M, Yamao K, Mizuno N, et al. Randomized phase II/III clinical trial of elapomotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Cancer Sci. 2015;106(7):883–90.

53. Lawson DH, Lee S, Zhao F, Tarhini AA, Margolin KA, Ernstoff MS, et al. Randomized, placebo-controlled, phase III trial of yeast-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) versus peptide vaccination versus gm-csf plus peptide vaccination versus placebo in patients with no evidence of disease after complete surgical resection of locally advanced and/or stage IV melanoma: a trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). J Clin Oncol. 2015;33(34):4066–76.

54. Mittendorf EA, Lu B, Melisko M, Price Hiller J, Bondarenko I, Brunt AM, et al. Efficacy and safety analysis of nelinepimut-s vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase III clinical trial. Clin Cancer Res. 2019;25(14):4248–54.

55. Clifton GT, Peoples GE, Mittendorf EA. The development and use of the E75 (HER2 369–377) peptide vaccine. Future Oncol. 2016;12(11):1321–9.

56. Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Yamaue H, et al. Abagovomab as maintenance therapy in patients with advanced renal cell carcinoma (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008;372(9633):145–54.

57. Testori A, Richards J, Whitman E, Mann GB, Lutzky J, Cama-cho L, et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine,
with physician’s choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol. 2008;26(6):955–62.

58. Bloch O, Shi Q, Anderson SK, Knopp M, Raizer J, Clarke J, et al. ATIM-14. ALLIANCE A071101: a phase II randomized trial comparing the efficacy of heat shock protein peptide COM-PLEX-96 (HSPPC-96) vaccine given with bevacizumab versus bevacizumab alone in the treatment of surgically resectable recurrent glioblastoma. Neuro-Oncology. 2017;19(suppl_6):v129.

59. Forster V. Cancer Therapy Advisor. Phase 3 trial for oncolytic viral therapy pexa-vec in advanced liver cancer terminated early. 2019. https://www.cancertherapyadvisor.com/home/cancer-topic/general-oncology/phase-3-trial-for-oncolytic-viral-therapy-pexa-vec-in-advanced-liver-cancer-terminated-early/2/. Accessed 24 June 2020.

60. Kumai T, Fan A, Harabuchi Y, Celis E. Cancer immunotherapy: moving forward with peptide T cell vaccines. Curr Opin Immunol. 2017;47:57–63.

61. Kumai T, Kobayashi H, Harabuchi Y, Celis E. Peptide vaccines in cancer-old concept revised. Curr Opin Immunol. 2017;45:1–7.

62. Mellman I, coukos G, dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480–90.

63. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, van der Burg SH, Offringa R. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol. 2008;38(4):1033–42.

64. Faure F, Mantegazza A, Sadaka C, Sedlik C, Jotereau F, Amigorena S. Long-lasting cross-presentation of tumor antigen in human DC. Eur J Immunol. 2009;39(2):380–90.

65. Rosalia RA, Quakelaar ED, Redeker A, Khan S, Camps M, Driehout JW, et al. Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. Eur J Immunol. 2013;43(10):2554–65.

66. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Persson DF, et al. sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.

67. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–8.

68. McKay RR, Hafron JM, Ferro C, Wilkehrt HM, Fitch K, Fratten SC, et al. A retrospective observational analysis of overall survival with sipuleucel-T in Medicare beneficiaries treated for advanced prostate cancer. Adv Ther. 2020;37(12):4910–29.

69. Huang X, Ye D, Thorpe PE. Enhancing the potency of a whole-cell breast cancer vaccine in mice with an antibody-IL-2 immunocytokine that targets exposed phosphatidylserine. Vaccine. 2011;29(29–30):4785–93.

70. Graner MW, Likhacheva A, Davis J, Raymond A, Brandenberger J, Romano ska A, et al. Cargo from tumor-expressed albumin inhibits T-cell activation and responses. Cancer Res. 2004;64(21):8085–92.

71. Aleynick M, Svensson-Arvelund J, Flowers CR, Marabelle A, Brody JD. Pathogen molecular pattern receptor agonists: treating cancer by mimicking infection. Clin Cancer Res. 2019;25(21):6283–94.

72. Kantoff PW, Galley JL, Pico-Navarro C. Revised overall survival analysis of a phase II, randomized, double-blind, controlled study of PROSTVAC in men with metastatic castration-resistant prostate cancer. J Clin Oncol. 2017;35(1):124–5.

73. Kilman DM, Yamshchikov G, Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol. 1997;158(8):3635–9.

74. Antonelli AC, Binyamin A, Hohl TM, Glickman MS, Redelman-Sidi G. Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-γ signaling. Proc Natl Acad Sci USA. 2020;117(31):18627–37.

75. Toda M, Martuza RL, Rabkin SD. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol Ther. 2000;2(4):324–9.

76. Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10(4):292–303.

77. Kaufman HL, Kim DW, DeRaf flele G, et al. Local and distant immunity induced by intraliesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010;17(3):718–30.

78. Joffre OP, Segura E, Savina A, Amigorena S. Crossresentation by dendritic cells. Nat Rev Immunol. 2012;12(8):557–69.

79. Yanagisawa R, Koizumi T, Koya T, Sano K, Koido S, Nagai K, et al. WT1-pulsed dendritic cell vaccine combined with chemotherapy for resected pancreatic cancer in a phase I study. Anti cancer Res. 2018;38(4):2217–25.

80. Crosby EJ, Gwin W, Blackwell K, Marcom PK, Chang S, Maec ker HT, et al. Vaccine-induced memory CD8+ T cells provide clinical benefit in HER2 expressing breast cancer: a mouse to human translational study. Clin Cancer Res. 2019;25(9):2725–36.

81. Ueda Y, Ogura M, Miyakoshi S, Suzuki T, Heike Y, Tagashira S, et al. Phase I/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome. Cancer Sci. 2017;108(12):2445–53.

82. Tsuibo A, Hashimoto N, Fujiki F, Morimoto S, Kagawa N, Nakajima H, et al. A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma. Cancer Immunol Immunother. 2019;68(2):331–40.

83. Ogawara M, Miyashita M, Yamagishi Y, Ota S. Phase I/II pilot study of Wilms’ tumor 1 peptide-pulsed dendritic cell vaccination combined with conventional chemotherapy in patients with head and neck cancer. Ther Apher Dial. 2019;23(3):279–88.

84. Nishida S, Ishikawa T, Egawa S, Koido S, Yanagimoto H, Ishii J, et al. Combination gemcitabine and WT1 peptide vaccination improves progression-free survival in advanced pancreatic ductal adenocarcinoma: a phase II randomized study. Cancer Immunol Res. 2018;6(3):320–31.

85. Miyakoshi S, Usuki K, Matsumura I, Ueda Y, Iwasaki H, Miyamoto T, et al. Preliminary results from a phase 1/2 study of DSP-7888, a novel WT1 peptide-based vaccine, in patients with myelodysplastic syndrome (MDS). Blood. 2016;128(22):4335.

86. Matsuda T, Takeuchi H, Sakurai T, Mayanagi S, Fujita T, et al. Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer. Oncol Lett. 2018;16(1):1348–56.

87. Maslak PG, Doo T, Bernal Y, Chanel SM, Zhang R, Frattini M, et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinepeptim-S) in acute myeloid leukemia. Blood Adv. 2018;2(3):224–34.

88. Katsuda M, Miyazawa M, Ojima T, Katanuma A, Hakamada K, Sudo K, et al. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLPO-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy. Trials. 2019;20(1):242.

89. Hirabayashi K, Yanagisawa R, Saito S, Higuchi Y, Koya T, Sano K, et al. Feasibility and immune response of WT1 peptide vaccination in combination with OK-432 for paediatric solid tumors. Anticancer Res. 2018;38(4):2227–34.
Hanada S, Tsuruta T, Haraguchi K, Okamoto M, Sugiyama H, Koido S. Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines. Hum Vacc Immunother. 2019;15(2):397–406.

De Groot JF, Cloughesy TF, Pitz MW, Narita Y, Nonomura T. A randomized, multicenter phase 2 study of DSP-7888 dosing emulsion in combination with bevacizumab (Bev) versus Bev alone in patients with recurrent or progressive glioblastoma. J Clin Oncol. 2018;36(15_suppl):TPS2071.

Fu S, Piccioni DE, Liu H, Vincas Lucas R, Aregawi D, Yamauchi S, Berneman ZN, Anguille S, Willemen Y, Van de Velde A, Gerasimov SELLAS Life Sciences Group. SELLAS Life Sciences announces review of strategic alternatives. 2019. https://www.sellaslife sciences.com/investors/news/News-Detai ls/2019/SELLAS-Life-Sciences-Announces-Review-of-Strategic-Alternatives/default.aspx. Accessed 12 July 2019.

Hilf N, Kutttruff-Coqui S, Frenzel K, Bukur V, Stevanovic S, Gouttefangeas C, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019;565(7738):240–5.

Tran NH, Qiao R, Xin L, Chen X, Liu C, Zhang X, et al. Deep learning enables de novo peptide sequencing from data-independent-acquisition mass spectrometry. Nat Methods. 2019;16(1):63–6.

Tran NH, Qiao R, Xin L, Chen X, Shan B, Li M. Personalized deep learning of individual immunopeptidomes to identify neoantigens for cancer vaccines. Nat Mach Intell. 2020;2:764–71.

Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford PR. Peptides as cancer vaccines. Curr Opin Pharmacol. 2019;47:20–6.

Cho HI, Barrios K, Lee YR, Linowski AK, Celis E, BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8+ T-cell responses. Cancer Immunol Immunother. 2013;62(4):787–99.

Kumai T, Lee S, Cho HI, Sultan H, Kobayashi H, Harabuchi Y, et al. Optimization of peptide vaccines to induce robust antitumor CD4+ T-cell responses. Cancer Immunol Immunother. 2017;66(1):72–83.

Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, et al. Systemic immunity is required for effective cancer immunotherapy. Cell. 2017;168(3):487-502.e15.

Kim HJ, Cantor H. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol Res. 2014;2(2):91–8.

Gard AD, Coulie PG, Van den Eynde BJ, Agostinis P. Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape. Trends Immunol. 2017;38(8):577–93.

Santos PM, Butterfield LH. Dendritic cell-based cancer vaccines. J Immunol. 2018;200(2):443–9.

Bol KE, Schreibelt G, Rabold K, Wculek SK, Schwarze JK, Dzioniak A, et al. The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. J Immunother Cancer. 2019;7(1):109.
125. Schreibelt G, Bol KF, Westdorp H, Wimmers F, Aarnzen EH, Duiveman-de Boer T, et al. Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells. Clin Cancer Res. 2016;22(9):2155–66.

126. Tel J, Aarnzen EH, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res. 2013;73(13):3063–75.

127. Westdorp H, Oort IM, Creemers JHA, Schreibelt G, Mehra N, de Goede AL, et al. Myeloid and plasmacytoid dendritic cell vaccinations for castration-resistant prostate cancer patients. J Clin Oncol. 2018;36(6_suppl):219.

128. Hammerich L, Marron TU, Upadhyay R, Svensson-Arvelund J, Dhainaut M, Hussein S, et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019;25(5):814–24.

129. Lim M, Badruddoza AZM, Firdous J, Azad M, Mannan A, Al-Hilal TA, et al. Engineered nanodelivery systems to improve DNA vaccine technologies. Pharmaceutics. 2020;12(1):30.

130. Teixeira L, Medioni J, Garibal J, Adotevi O, Doucet L, Durey MD, et al. A first-in-human phase I study of INVAC-1, an optimized human telomerase DNA vaccine in patients with advanced solid tumors. Clin Cancer Res. 2020;26(3):388–97.

131. Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386(10008):2078–88.

132. Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534(7607):396–401.

133. Lopes A, Vandermeulen G, Preat V. Cancer DNA vaccines: current preclinical and clinical developments and future perspectives. J Exp Clin Cancer Res. 2019;38(1):146.

134. Soong RS, Trieu J, Lee SY, He L, Tsai YC, Wu TC, et al. Xenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53. PLoS ONE. 2013;8(2):e56912.

135. Groesenbaugh DA, Leard AT, Bergman PJ, Klein MK, Meleo K, Susaneck S, et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res. 2011;72(12):1631–8.

136. Bowen WS, Svrivastava AK, Batra L, Barsoumian H, Shirwan H. Current challenges for cancer vaccine adjuvant development. Expert Rev Vacc. 2018;17(3):207–15.

137. Wilson NS, El-Sukkari D, Villadangos JA. Dendritic cells constitutively present self antigens in their immature state in vivo and regulate antigen presentation by controlling the rates of MHC class II synthesis and endocytosis. Blood. 2004;103(6):2187–95.

138. Bonam SR, Partidos CD, Halmuthur SKM, Muller S. An overview of novel adjuvants designed for improving vaccine efficacy. Trends Pharmacol Sci. 2017;38(9):771–93.

139. Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak JE, Eguchi J, et al. Toll-like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med. 2007;5:10.

140. Naumann K, Wehner R, Schwarze A, Petzold C, Schmitz M, Rohayem J. Activation of dendritic cells by the novel Toll-like receptor 3 agonist RGC100. Clin Dev Immunol. 2013;2013:283649.

141. Kuai R, Oehyl LJ, Bahjat KS, Schwendeman A, Moon JJ. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat Mater. 2017;16(4):489–96.

142. Lynn GM, Sedlik C, Baharom F, Zhu Y, Ramirez-Valdez RA, Coble VL, et al. Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens. Nat Biotechnol. 2020;38(3):320–32.

143. Rao B, Han M, Wang L, Gao X, Huang J, Huang M, et al. Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review. J Transl Med. 2011;9:17.

144. Datta J, Fracol M, McMillan MT, Berk E, Xu S, Goodman N, et al. Association of depressed anti-HER2 T-helper type 1 response with recurrence in patients with completely treated HER2-positive breast cancer: role for immune monitoring. JAMA Oncol. 2016;2(2):242–6.

145. Lowenfeld L, Mick R, Datta J, Xu S, Fitzpatrick E, Fisher CS, et al. Dendritic cell vaccination enhances immune responses and induces regression of HER2pos DCIS independent of route: results of randomized selection design trial. J Clin Cancer Res. 2017;23(12):2961–71.

146. Osada T, Hartman ZC, Wei J, Lei G, Hobeika AC, Gwin WR, et al. Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. Breast Cancer Res. 2018;20(1):90.

147. Ma L, Dichwalkar T, Chang JYH, Cossette B, Garafola D, Zhang AQ, et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science. 2019;365(6449):162–8.

148. Mould RC, AuYeung AWK, van Vloten JP, Susta L, Mutsaers AJ, Hilal TA, et al. Engineered nanodelivery systems to improve immunity to tumor antigens. Nat Med. 2019;25(5):814–24.

149. Miho E, Yermanos A, Weber CR, Berger CT, Reddy ST, Greiff AQ, et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science. 2019;365(6449):162–8.

150. Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak JE, Eguchi J, et al. Toll-like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med. 2007;5:10.

151. Naumann K, Wehner R, Schwarze A, Petzold C, Schmitz M, Rohayem J. Activation of dendritic cells by the novel Toll-like receptor 3 agonist RGC100. Clin Dev Immunol. 2013;2013:283649.

152. M. A. Morse et al.